SCHEMBL7701871

SCHEMBL7701871

CC(O)(C(=O)OCc1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
MEN1 O00255 2/20 0.48
PTPN1 P18031 2/20 0.46
PTPRC P08575 1/20 0.46
LMNA P02545 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2C P28335 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28955048 0.89 KMT2A (0.49) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL11838195 0.85 PTPN1 (0.44) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL28204990 0.85 MAOB (0.48) ALDH1A1KMT2AL3MBTL1MEN1PTPN1
SCHEMBL27558684 0.84 CHRM2 (0.58) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL24347012 0.84 ALDH1A1 (0.60) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL3756497 0.84 ALDH1A1 (0.60) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL11842561 0.82 MAOB (0.44) ALDH1A1L3MBTL1PTPN1PTPRCSMN1; SMN2
SCHEMBL11834116 0.82 PTPN1 (0.55) ALDH1A1KMT2AMAPK1MEN1PTPN1
SCHEMBL11835679 0.82 ALDH1A1 (0.48) ALDH1A1TDP1L3MBTL1PTPN1PTPRC
SCHEMBL11843128 0.82 ALDH1A1 (0.41) ALDH1A1KMT2ATDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof SYSTIMMUNE, INC. (US) 2026-03-17 US disclosed
CN-120131991-A Anti-human Claudin18.2 antibody-camptothecine drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2025-06-13 CN disclosed
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (CN) 2025-04-10 US disclosed
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF SYSTIMMUNE INC (US) 2025-02-20 US disclosed
CN-117752813-A anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof 成都百利多特生物药业有限责任公司 2024-03-26 CN disclosed
CN-116212044-A Anti-human Trop2 antibody-camptothecin drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2023-06-06 CN disclosed
CN-116120460-A Bispecific antibody-camptothecins drug conjugate and medical application thereof 成都百利多特生物药业有限责任公司 2023-05-16 CN disclosed
CN-113827736-A Camptothecin drug with high-stability hydrophilic connecting unit and conjugate thereof 四川百利药业有限责任公司 2021-12-24 CN disclosed
US-6414158-B1 INSECTICIDES, NEMATOCIDES BAYER AKTIENGESELLSCHAFT (DE) 2002-07-02 US disclosed
US-6342599-B1 REACTING SPECIFIED OXADIAZINE DERIVATIVES WITH ALKYLATING OR ACYLATING AGENTS, OR ALDEHYDES OR KETONES, OR THIONYLATING REAGENTS, IN PRESENCE OF DILUENT AND REACTION AUXILIARY IF REQUIRED BAYER AKTIENGESELLSCHAFT (DE) 2002-01-29 US disclosed
CN-1196056-A Cyclic Worm Inhibitors UPJOHN CO (US) 1998-10-14 CN disclosed
US-5683997-A MODULATION OF AT2 RECEPTOR CIBA-GEIGY CORPORATION (US) 1997-11-04 US disclosed
US-5610153-A ENZYME INHIBITORS; TREATMENT OF VASCULAR PROLIFERATION DISORDERS, STERILITY DYSFUNCTION, DYSMENORRHEA CIBA-GEIGY CORPORATION (US) 1997-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577325-B2 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof IGLV6-57, EGFR, ERBB2 ALDH1A1 3799/4885KMT2A 2519/4885TDP1 1675/4885
US-20250115679-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 ALDH1A1 1919/4885KMT2A 3730/4885TDP1 3050/4885
US-20250059296-A1 BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF ANTXR2, PAICS, CD38 ALDH1A1 1919/4885KMT2A 3730/4885TDP1 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.